← Search & browse all drugs
ALIMENTARY TRACT AND METABOLISM › OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS › OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS › Enzymes
agalsidase beta
A16AB04
Forms & Strengths
- Single-use vials of 5.5 mg/mL solution
- For intravenous infusion only
Adult Dosing
- 1 mg/kg body weight every other week
- Administer as an intravenous infusion over 40 minutes to 4 hours
Pediatric Dosing
- 1 mg/kg body weight every other week
- No dose adjustment for pediatric patients
Indications
- Treatment of adults with Fabry disease
- Treatment of patients with Fabry disease
Mechanism of Action
- Replaces the human enzyme alpha-Galactosidase A
- Reduces globotriaosylsphingosine levels
Contraindications
- Hypersensitivity to agalsidase beta or other components
Adverse Reactions
- Infusion-related reactions
- Nausea and vomiting
- Headache and fatigue
- Dizziness and paresthesia
Drug Interactions
- None well-documented
- Caution advised with other intravenous drugs
Curated Content: Needs Vetting Before Put to Clinical Use